Duke University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Duke University sits in the top decile of US sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count).
Duke University: 1,725 sponsored US clinical trials, 187 recruiting.
Duke University sponsors 1,725 registered US clinical trials on ClinicalTrials.gov, 187 of them currently recruiting, and 1,244 completed. 175 of these trials are in Phase 3-4 (later-stage) and 311 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.
Top-decile sponsor footprint
Duke University ranks in the top decile of sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,244 of 1,444 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,725 total, page 12 of 35
Individual Patient Exposure and Response in Pediatric Lupus
NCT04358302
RESILIENCE: Personalizing Cardiovascular Health
NCT04551872
Patient-Derived Organoids for Rectal Cancer
NCT04371198
Skeletal Muscle Health in Children With Type 1 Diabetes
NCT04288063
Project Uplift: Substance Use and Mental Health Treatment for Young Sexual and Gender Minorities
NCT04546061
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
NCT04352777
Exploring Two Treatments for Misophonia
NCT04198597
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
NCT04226131
Persistent Postpartum Hypertension Pilot Trial
NCT04349124
Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT04352439
COA-APTIC Clinician Concept Elicitation Study
NCT04380246
Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia
NCT04158752
Daxor - Blood Volume Analysis
NCT04111185
Perioperative Tissue Penetration of Antimicrobials in Infants
NCT04299867
Genetic Testing to Understand and Address Renal Disease Disparities Across the United States
NCT04191824
Genetic Testing to Understand and Address Renal Disease Disparities Across the United States Pharmacogenetic Substudy
NCT06748040
Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib
NCT04099836
Expedited Versus Restrictive: Limitations on Activity Following Surgical Treatment of Prolapse
NCT04329715
Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19
NCT04399252
MURDOCK Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study
NCT04424004
Reducing Obesity and Cartilage Compression in Knees
NCT04730557
Expressive Writing for COVID-19 Resilience for Parents
NCT04589117
Expressive Writing for COVID-19 Resilience
NCT04589104
Pattern - Reach Aim 2
NCT04216264
NeuroCognition After Carotid Recanalization
NCT04219774
Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)
NCT04350073
Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection
NCT04335552
Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19
NCT04342806
A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib
NCT04253223
COVID-19 Pandemic Response Network
NCT04320862
Self-System Therapy for Older Adults With Lung Cancer
NCT04057196
Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer
NCT03964337
Virtual Reality for Improving Pain and Distress in Patients With Advanced Stage Colorectal Cancer
NCT04069702
HiLo: Pragmatic Trial of Higher vs Lower Serum Phosphate Targets in Patients Undergoing Hemodialysis
NCT04095039
Identification and Characterization of Novel Non-Coding Variants That Contribute to Genetic Disorders
NCT04399694
AdheRence to Inhaled Corticosteroids in Asthma
NCT03769519
Physical Resilience: Indicators and Mechanisms in the Elderly (PRIME) Collaborative Phase 2
NCT04235309
Sleep Quality and Mechanisms of Cardiovascular Risks in Adults With Hypertension
NCT04009447
Emergency Department Acupuncture for Acute Musculoskeletal Pain Management
NCT04290741
Arterial Versus Venous Activated Clotting Time (ACT) Measurements During Atrial Fibrillation Ablations
NCT04285840
Splanchnic Nerve Block for Therapy of Chronic Heart Failure (Splanchnic III)
NCT04575428
Improving the Clinical Encounter to Enhance Delivery of an Individualized Prematurity Prevention Plan
NCT04149002
CSF/Serum Biomarkers in Predicting PND/Persistent Pain After Cesarean
NCT04271072
Symptom Management for YA Cancer Survivors
NCT04035447
Respiratory Muscle Training (RMT) in ALS
NCT04224961
Selah Trial of Stress Interventions for Clergy: Mindfulness Based Stress Reduction, Daily Examen, and Stress Inoculation
NCT04625777
Clinical Trials in Organ Transplantation Extension Study
NCT04126746
Hypertension Management in Cancer Patients
NCT03919214
BEST vCLI Registry
NCT04191746
Quality Improvement Project for Advance Care Planning Tool in Hospital Medicine
NCT04296136
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 136 |
| Phase 2 | 175 |
| Phase 3 | 41 |
| Phase 4 | 134 |
Therapeutic Areas
What is open in the Duke University pipeline
187 recruiting of 1,725 indexed (11% open); 1,244 completed (72%).
Phase mix: 175 late (III/IV) vs 311 early (I/II) (early-phase heavy).
Top condition: Obesity (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Duke University: open-pipeline peers nationwide
Peers matched on 1,725 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,725 trials (± recruiting share)
- University of California, San Francisco · 1,713 trials · 16% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 11% open enrollment (± trial volume)
- Carnegie Mellon University · 11% recruiting · 37 trials
- CAMC Health System · 11% recruiting · 28 trials
- UConn Health · 11% recruiting · 178 trials
- Hartford Hospital · 11% recruiting · 75 trials
Related
What to do with this Duke University page
1,725 registered trials is a research-attention snapshot, not an endorsement of Duke University or any single study.
- 187 of Duke University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Duke University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Duke University pipeline card: 1,725 registered trials from official public datasets.Report a data error.